Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 0.73 |
| ▸ | ITGB3 | P05106 | 18/20 | 0.73 |
| ▸ | ITGB6 | P18564 | 3/20 | 0.51 |
| ▸ | ITGB8 | P26012 | 3/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.51 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.51 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.51 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7936710 | 1.00 | ITGAV (0.73) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL7944256 | 0.91 | ITGAV (0.82) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL7944250 | 0.91 | ITGAV (0.82) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL3888089 | 0.87 | ITGAV (0.82) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL3888804 | 0.85 | ITGAV (1.00) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL7945568 | 0.85 | ITGAV (1.00) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL3888492 | 0.85 | ITGAV (1.00) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL3888493 | 0.85 | ITGAV (1.00) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL7945753 | 0.84 | ITGAV (0.77) | ITGAVITGB3ITGB6ITGB8ITGA2B | |
| SCHEMBL4045472 | 0.84 | ITGAV (0.79) | ITGAVITGB3ITGB6ITGB8ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6268378-B1 | TREATING AND PREVENTING OSTEOPOROSIS, AND INHIBITING VASCULAR RESTENOSIS, DIABETIC RETINOPATHY, MACULAR DEGENERATION, ANGIOGENESIS, ATHEROSCLEROSIS, INFLAMMATION, VIRAL DISEASE, AND TUMOR GROWTH. | MERCK & CO., INC. | 2001-07-31 | — | — | US | claimed |
| EP-1047425-A4 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2009-04-22 | — | — | EP | disclosed |
| US-6268378-B1 | TREATING AND PREVENTING OSTEOPOROSIS, AND INHIBITING VASCULAR RESTENOSIS, DIABETIC RETINOPATHY, MACULAR DEGENERATION, ANGIOGENESIS, ATHEROSCLEROSIS, INFLAMMATION, VIRAL DISEASE, AND TUMOR GROWTH. | MERCK & CO., INC. | 2001-07-31 | — | — | US | disclosed |
| EP-1047425-A1 | INTEGRIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2000-11-02 | — | — | EP | disclosed |
| US-6066648-A | USEFUL IN INHIBITING BONE RESORPTION, TREATING AND PREVENTING OSTEOPOROSIS, AND INHIBITING VASCULAR RESTENOSIS, DIABETIC RETINOPATHY, MACULAR DEGENERATION, ANGIOGENESIS, ATHEROSCLEROSIS, INFLAMMATION, VIRAL DISEASE, AND TUMOR GROWTH | MERCK & CO., INC. (US) | 2000-05-23 | — | — | US | disclosed |
| WO-1999030709-A1 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1999-06-24 | — | — | WO | disclosed |